Abstract: Microglial cells are the resident phagocytic cells of the central nervous system (CNS). They possess a wide range of receptors allowing them to identify and internalize numerous pathogens. We will discuss here the role of the most important receptors of microglia involved in non-opsonin-dependent phagocytosis (mannose receptor, β-glucan receptor, scavenger receptor) and that of receptors involved in the opsonin-dependent phagocytosis, namely the complement 3 (CR3) and the Fcγ receptors (FcγR). First, the molecular and cellular mechanisms induced when these receptors are conducting a phagocytic event are presented. In the second part, we will discuss the role these receptors may play in multiple sclerosis and Alzheimer's disease, in the elimination by phagocytosis of myelin and beta amyloid peptide respectively.
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The cerebral immune system
The central nervous system (CNS) is protected by a specific immune system. The CNS possesses different chemical and physical barriers as a means to protect itself from the damages caused by the inflammation of peripheral tissues. The cerebrospinal fluid (CSF) is produced by the choroid plexus cells in the ventricules. It cushions the brain and it is contained within the three layers of meninges (the dura matter, the arachnoid and the pia matter) that act as a physical barrier. The blood-brain barrier (BBB) is a specialized system of capillary endothelial cells that protects the brain from harmful substances present in the blood stream, while supplying the brain with the required nutrients for proper function. Unlike peripheral capillaries that allow relatively free exchange of substance across and between cells, the BBB strictly limits transport into the brain through both physical (tight junctions) and metabolic (enzymes) barriers. Thus the BBB is often the rate-limiting factor in determining permeation of therapeutic drugs into the brain. Chemical defense mechanisms include locally produced molecules with anti-inflammatory properties such as transforming growth factor (TGF) β, which is present in the CSF and which exerts a negative chemotactic effect on the leukocytes which attempt to infiltrate CNS [1] . Immune system cells that would succeed in entering the CNS are eliminated by apoptosis, mediated by the CD95 receptor and its ligand [2] .
The CNS is guarded by professional macrophages which are widely distributed in sites in which they might encounter CNS antigens. These sites include the dura matter, leptomeninges, and the choroid plexus [3] . The presence of rich, important networks of microglial cells in the vascular and supporting tissues of the brain cerebral parenchyma may play an important role in inflammatory and immune-mediated disorders affecting the CNS, and control the entry of blood-circulating immune cells and pathogens.
Microglial cells of the cerebral parenchyma are in a quiescent state. Under physiological stimulation or stress conditions, they are transformed into fully immuno-competent cells and become activated. They undergo morphological changes (acquisition of a rounded shape) and functional changes (acquisition of proliferative, secretory, phagocytic and antigen-presenting cells properties). Their major changes involve their capacity to eliminate by phagocytosis and present antigen. In this way, activated microglial cells greatly resemble fetal amoeboid cells.
Activation of ramified microglial cells
Microglial cells are activated in vitro when exposed to different pathogens such as viruses, bacteria or parasites. In vivo, they are also activated in cases of cerebral lesions, tumors, and neurodegenerative diseases or auto-immune diseases. When submitted to such activating stimuli, microglial cells retract their ramifications, take a round shape and are recruited by a chemotactic signal to the affected regions in order to eliminate the disturbing factors. The activating signal that leads to the activation of microglial cells can be of two different origins: (a) it can originate from either the pathogenic element itself or (b) it can originate from secreted mediators (cytokines) that astrocytes and microglia release after being activated. In the first case, the activation involves a broad range of receptors that recognize a large spectrum of molecules. In the second case, activation of microglial cells depends on the cytokine receptors.
In vitro activation of microglial cells
Bacterial lipopolysaccharide (LPS) can activate microglial cells in vitro and is widely used for this purpose in order to activate them. After LPS treatment, microglial cells produce a wide range of cytokines such as tumor necrosis factor (TNF) α, interleukin (IL)-1, IL-6 [4] , prostaglandins, and chemokines such as MIP-1 and RANTES [5] . LPS can also activate the inducible NO synthase (iNOS) and hence induce the production of NO by microglial cells [6] .
LPS is a commonly used stimulator but there exists other activators of the microglial cells in vitro that are found in different pathological states, such as Aβ (brain of AD patients), the prion protein, and HIV proteins.
Inhibitors of microglial activation in vitro
In addition to the activators of microglia, inhibitors of this activation exist, among which are growth factors such as nerve growth factor, brain-derived neurotrophic factor or neurotrophin 3, which decrease the IFNγ-induced expression of class II major histocompatibility complex [7] . Prostaglandins inhibit the production of TNFα and IL-1 after activation of the cells with LPS [8] . Steroids such as dexamethasone also have a deactivating effect on activated microglia by decreasing the production of NO [9] . Neuronal mediators, such as β-adrenergic agonists and glutamate, decrease the activation of microglia. Astrocytes can affect the LPS-induced activation of microglia by secreting TGFβ, which leads to a decrease in the expression of the iNOS [10, 11] .
Cell-cell contact plays a role in the activation of microglial cells [12] . CD200 receptor, expressed by neurons and endothelial cells, can decrease the activation of microglial cells by interacting with CD200 expressed by myeloid cells. CD200 deficient mice have less ramified microglial cells that over-express the integrin CD11b/CD18 (known as complement receptor 3, CR3) and CD45 [13] .
Migration of microglial cells and elimination of pathogens
During an experimentally-induced inflammatory reaction of the CNS, a great number of activated microglial cells are found in the brains of affected animals [14] . All types of brain cells are potential chemokine sources. In vivo and under non pathological conditions, microglial cells express several chemokine receptors like the CCR-3, the CCR-5 [15] and the CXCR-4 [16, 17] , and, in vitro, the CX3CR-1 [18] . The different molecules acting on these receptors are responsible for the migration of microglial cells to the inflammatory sites (for review on chemokines and chemokines receptors see [19] ). However, recent studies have shown that mechanisms other than the well-described chemokines and chemokine receptor system can trigger chemotactic activity. Indeed, neurotensin can act on its human microglial cell line receptor i.e. neurotensin receptor-3 and induce microglial migration by a mechanism dependent on both phosphatidylinositol-3 kinase (PI3K) and mitogenactivated protein kinase pathways. In the murine microglial cell line N11, the neurotensin receptor-3 is also the only neurotensin receptor expressed, and its activation by its ligand leads to the phosphorylation of both Erk1/2 and Akt. In these cells, neurotensin induces the gene expression of several cytokines/chemokines, including MIP-2, macrophage chemotactic protein, IL-1 and TNFα [20] . Similarly, ion channels have been shown to be able to modulate or facilitate migration of microglial cells by regulating membrane potential, cell volume and intracellular ion concentrations [21] .
It has been suggested that local microglial cells transform into brain macrophages after the injection of toxic lectin from Ricinus communis into the rat facial nerve, resulting in rapid degeneration of facial motor neurons [22] . Activation, therefore, transforms ramified microglial cells into professional phagocytes. By expressing a variety of receptors, microglial cells can internalize a great number of particles such as latex beads or bacteria [23] , IgG-opsonized erythrocytes [24] , zymosan [25, 26] , apoptotic bodies [27] and heat-killed yeasts [28] .
Activation of microglial cells leads to the up-regulation of certain receptors (Table 1 ). In the case of multiple sclerosis [MS] , microglial cells up-regulate the expression of FcγRI, II and III [29] and CR3 [30] . Microglial cells are also activated under some pathological conditions: Aβ can activate and induce the migration of human microglia [31] , or rat microglial cells [32] . Microglial cells react to Aβ by releasing proinflammatory chemokines, cytokines [33, 34] , and free radicals [35, 36] . 
Microglial cells and phagocytosis
Microglial cells recognize and engulf a wide range of pathogens. They express receptors capable of identifying molecular structures of pathogens such as the LPS of Gram negative bacteria, lipoteichoic acid of Gram positive bacteria, mannans and glucans of a variety of microorganisms. These structures are called pathogen-associated molecular pattern and their receptors that identify them are called pattern-recognition receptors. The pathogenassociated molecular pattern can also be recognized by soluble receptors called opsonins that bind to the pathogens and allow the elimination of the complex subsequently formed by opsonin receptors of microglia. We will expose the microglial receptors known to trigger an opsonin independent phagocytosis as well as those involved in the opsonin dependent phagocytosis (Table 2) . It is worthy noting that, in the CNS, the phagocytic activity of microglial cells does not impair their capacity to support neuronal survival [37] [38] . MR is expressed in vivo in the post-natal murine brain and its expression is developmentally regulated: the expression peak is reached in the first week of life and it dramatically decreases thereafter, being maintained at a low level throughout adulthood. MR is expressed by cells located in most brain regions at an early post-natal age, the site of the most intense expression being the meninges, followed by the cerebral cortex, brain stem and the cerebellum. With age, expression of the MR is restricted to the cerebral cortex and the brain stem. In healthy brain, oligodendrocytes, ependymal cells, endothelial cells or parenchymal microglial cells do not express MR. The mannose receptor is expressed by perivascular macrophages/microglia and meningeal macrophages [39] . This pattern of expression is maintained in inflamed, injured, and diseased CNS of mice [40] .
However, rodent cultured microglial cells express MR. Microglial MR expression is upregulated in response to anti-inflammatory substances such as IL-4 or dexamethasone and downregulated after treatment by pro-inflammatory mediators IFNγ or LPS [41, 42] . This differential response to anti-or pro-inflammatory molecules has been previously described in peripheral macrophages [38, 43, 44] .
The phagocytic function of microglial MR has not been widely described yet. To the best of our knowledge, we have been the first to describe it in a murine microglial cell line. Indeed, the uptake of heat-killed yeast was reduced in the presence of α-mannans, a commonly used ligand of MR [45, 46] . However, primary cultured microglial cells are able to endocyte different mannosylated ligands such as horseradish peroxydase [41, 42] and mannosylated-BSA [42] through the MR. Mannosylated molecules are present at the surface of various pathogens and are a pathogen-associated molecular pattern. This suggests that the MR expressed in these primary cultured microglia can bind and eliminate microorganisms by phagocytosis. Indeed, in peripheral macrophages, MR recognizes and internalizes by its CTLD domain many microorganisms, among which Candida albicans [47] , Pneumocystis carinii [48] , HIV [49] , Klebsiella pneumoniae [50] , Leishmania [51] and Streptococcus pneumoniae [50] . Yeast and Leishmania can be internalized by MR-transfected cells [52, 53] .
Although it was known that MR controls signaling events occurring during activation of the cells even though its intracytoplasmic tail lacks signaling motifs (LPS-activated cells produced IL-12 in the presence of an anti-MR antibody [54] and transcription factor NFkB is activated after MR interacts with P. carinii but not soluble LPS [55] ), the molecular mechanisms that mediate the polymerization of actin after binding of pathogens to MR have been only recently clarified. The family of small Rho guanosine triphosphatases (GTPases) includes Cdc42, Rac, and Rho, they link membrane receptors to the actin cytoskeleton. Therefore, they control various biological processes like phagocytosis. Zhang et al. (2005) [56] have shown that Cdc42 and RhoB activation are required for MRmediated phagocytosis of P. carinii by human alveolar macrophages. Therefore, it is believed that the MR-mediated phagocytosis resembles FcγR-mediated phagocytosis even though it does not induce an inflammatory reaction [57] but rather attenuates it [58, 59] .
Recent studies have shown that MR does not promote particle ingestion in non phagocytic cells on its own. Transient expression of MR in two human cell lines did not provide them with a phagocytic function. It has been suggested that MR is a binding receptor, which requires a partner to trigger phagocytosis in some specialized cells such as macrophages [60] .
β-glucan receptor
The putative β-glucan receptor was first identified as a receptor capable of ingesting zymosan [61] . Since this inaugural study, several membrane receptors were presented as serious candidates to be the β-glucan receptor, among which lactosylceramide receptor [62] , scavenger receptors, CR3 and dectin-1. The expression pattern of the β-glucan receptors is rather large and all these proteins, more or less studied for their capacity to bind β-glucan, are expressed in brain macrophages [63] . In the absence of opsonins the phagocytosis of zymosan is blocked by laminarin, a soluble molecule extracted from Laminaria digitata which shares several similarities in structures with the β-D glucans [64] . The β-glucan receptors expressed by the microglial cell lines BV-2 and MAMI were shown to be fully functional in phagocytosis of unopsonized heat-killed yeast particles [65, 66] .
Besides its capacity to bind the complement component iC3b deposited on cell surfaces [67] (for the opsonin-dependent phagocytosis through CR3 see section 3.2.1 below), CR3 also possesses a lectin site that binds polysaccharides of microbial origin and triggers an opsonin-independent phagocytosis. Expression of CR3 induces a four-fold increase in the ingestion of zymosan, Mycobacterium kansasii and Mycobacterium avium in CHO cells in the absence of opsonin [68] . Polysaccharides and anti-CR3 mAbs recognizing different regions of the receptor have differential inhibitory effects on phagocytosis of zymosan by CR3-transfected CHO cells. Therefore, it has been proposed that distinct regions of CR3 are involved in the nonopsonic phagocytosis of mycobacteria and zymosan, and transduce different intracellular signals [68] .
Dectin-1 is the only β-glucan receptor identified in vivo [69, 70] . It has a 25 kD molecular weight. It contains an immunoreceptor tyrosine-based activation motif (ITAM) in its intracytoplasmic side tail. This motif activates tyrosine kinases. The transmembrane domain is a CTLD domain with two glycosylation sites [71] . Anti-dectin-1 antibody but not anti-CD11b antibody can inhibit the macrophage phagocytosis of unopsonized zymosan particles by macrophages [72] proving that dectin-1 is a β-glucan receptor. Dectin-1 can interact with endogen ligands [72] . It plays a major role in immunity, including activation of macrophages as well as natural killer cells and neutrophils in vitro, and promotion of resistance to infections and tumors in vivo [73] . Investigation into the role of these oligosaccharides structures is complicated by their multiplicity and the possible existence of overlapping specificities.
Scavenger receptors
The scavenger receptors (SR) are characterized by high affinity binding of a range of different ligands such as acetylated or oxidated LDL (acLDL or oxLDL), methylated BSA, polynucleotides (poly I and poly G, but not poly A or poly C), acidic phospholipids (phosphatidylserine), polysaccharides (dextran sulfate and fucoidan) and bacterial lipoteichoic acids and endotoxins LPS [74, 75] . SR are categorized into three classes (A, B and C), based on their structure and ligand specificities. Neonatal microglial cells express SR-A and SR-B1 and microglial cells of normal adult mouse and human brains do not express them [76] . However, under pathological conditions, the SR-A and SR-B reappear on activated microglial cells.
There exist several subclasses of the SR-A, namely: SR-A class I, II, III and the macrophage receptor with collagenous domain (MARCO) [77] . SR-AI and II are homotrimeric glycoproteins composed of three 77 kD monomers. Both classes exhibit nearly identical ligand specificity [78] whereas SR-AIII, which lacks exon 10 of the SR-A gene, is unable to mediate the uptake of ligands and acts as a dominant negative regulator in the trimeric SR-A molecule. SR-AI and II, expressed by neonatal microglial cells, mediate the binding and phagocytosis of apoptotic cells that express phosphatidylserine [79] . Such as SR-AI and II, MARCO binds modified LDL and is expressed on microglial cells [80] . Its potential role in clearance of debris and degenerating cells in the brain is suggested by its up-regulation in the mouse cortex after a prolonged ischemia [81] .
The SR-B subfamily comprises CD36 and SR-B1 [82] . CD36 is an 88 kD glycoprotein expressed in several types of cells (macrophages, adipose tissue, epithelial cells, monocytes [83, 84] ). SR-BI has a molecular weight of 55 kD and is expressed on adipose, lung and liver tissue. Both receptors bind modified ligands (acLDL, oxLDL, methylated BSA), and phosphatidylserine. However, they do not bind the broad large polyanionic ligands that are recognized by SR-A, but bind native LDL [85] . In addition SR-B1 binds HDL [85] . The role SR-B1 is playing in phagocytic process is unclear. Recently, Zhang et al . [86] suggested that SR-B1 was involved in the recognition and the internalization of phosphatidylserine-liposome in microglial cells. However, this process may require the cooperation of the phosphatidylserine receptor. Conversely, it is well documented that CD36 is a major phagocytic receptor involved in apoptotic body removal [87] , Plasmodium falciparum infected-cells [88] and recently Staphylococcus aureus [89] .
Opsonin-dependent phagocytosis 3.2.1 Complement receptors
The complement system is a complex chain interaction of serum proteins, which have a chain interaction. Many of the early-involved components of the complement cascade are serine proteases which activate sequentially. There are two pathways by which complement system activation is initiated. Antibody-antigen complexes activate the classical pathway. The alternative pathway is initiated when a previously activated complement component binds to the surface of a pathogen. Activation of complement results in important biological effects which are opsonization, inflammation, cell lysis and immunecomplexe clearance. Here, we will elucidate the role of CR3 in phagocytosis.
CR1 is a multifunctional receptor which binds C3b and C4b [90] . CR1 is expressed on erythrocytes, where it plays a vital role in removing immune complexes from circulation [91] . It is found on macrophages where it is implicated in phagocytosis [92] and on circulating monocytes and neutrophils, but the major site of expression is Blymphocytes [90] . CR1 plays an important regulatory role in cellular immunity [93] .
CR3 is implicated in phagocytosis of Escherichia coli by amoeboid microglial cells in the corpus callosum of 1-day-old rats [94] . Morphine enhances CR-mediated phagocytosis of Cryptococcus neoformans by human microglia [95] . CR3 binds iC3b. It is expressed in monocytes, macrophages, neutrophils and microglia in vitro as well. It triggers phagocytosis of opsonized particles, either in concert with FcγR receptors or independently of them [96] . It is stimulated by IFNγ and inhibited by TGFβ [97] .
Phagocytosis of microorganisms via CR3, and or via CR3+FcγR, is a major mechanism of defense against bacterial and fungal infection. CR3 binds a great variety of ligands such as coagulation factor X, intercellular adhesion molecule ICAM-1 and ICAM-2 and LPS [98] .
CR3-mediated phagocytosis is a type II phagocytosis, resulting from ligation of CR3 to complement component-opsonized particles. The engagement of CR3 leads to a "passive" phagocytic response, with the phagocytic target particles sinking into the cell membrane [99] . The intracellular signal triggered by a CR3-mediated opsonin-dependent phagocytosis requires actin microtubules [92] . Intracellular signaling of CR3 during the phagocytosis of iC3b-opsonized particles implicates PKC [100] . It also implicates PI3K [101] but not tyrosin kinases [102] . The intracellular signaling is transmitted by RhoA [103] .
Fc receptors
FcγR are among the best characterized phagocytic receptors. The three classes of FcγR are members of the immunoglobulin superfamily. Three groups of FcγR exist: FcγRI (CD64) present on macrophages, which recognize and internalize IgG-covered microorganisms, FcγRII (CD32) which is mainly expressed by macrophages and polynuclear neutrophils, and FcγRIII (CD16) expressed in NK cells and eosinophils [104, 105] . FcγRIIA, FcγRIIB, FcγRIIIA and FcγRIIIB have a weaker affinity for IgG and their activation requires a multivalent immunity complex [106] . All three classes of FcγR are expressed by murine microglial cells in vitro as shown by immunohistochemical staining [107] . The level of expression is weak in non-activated parenchymal microglia but increases when multiple sclerosis or injury is induced [29] . In human, FcγRI, II and III were detected in senile plaques and on ramified microglia throughout the cortex and white matter of normal and AD subjects [108] . IL-4, IL-1 and TNFα enhance FcγR expression on isolated rat brain microglial cells and TGFβ-1 downregulates it [109] . The FcγR expressed by cultured microglial cells is functional since microglia agglutinate and ingest IgG-sensitized erythrocytes [110] . LPS-stimulation allows the numbers of IgG-coated sheep erythrocytes ingested and their rate of ingestion by mouse microglial cells to increase [111] .
FcγR interaction with IgG leads to the internalization of the antibody-antigen complexes and to the release of cytokines and inflammation mediators [112] . Only FcγRIIB are inhibitory receptors whereas all the other FcγR have a cell activating profile function after they have bound their ligand [105] . Binding of the FcγR to immune complexes initiates a type I phagocytosis, characterized by extension of pseudopodia and envelopment of the phagocytic target particle [99] . This mechanism relies on the intracellular action of tyrosine kinases and the GTPases Rac and Cdc42 [103] .
FcγR consists of three chains: α, β and γ. The α chain is the one implicated in specific ligand recognition; β and γ chains play a major role in intracellular signaling. The activated FcγR possesses an ITAM, and an immunoreceptor tyrosin-based inhibitory motif (ITIM) that allows the receptor to respectively activate or inhibit tyrosine kinases [113] . Tyrosine residues in the ITAM of the γ subunit become phosphorylated. Mutation of either tyrosine residues results in a profound reduction in many transmembrane signaling events including cytosolic calcium fluxes, protein tyrosine phosphorylation and phagocytosis [114] . The early signaling events of FcγR mediated phagocytosis implicate the Src family tyrosine kinases such as Lyn, Fgr and Hck [115, 116] . Overexpression of Csk, a kinase that phosphorylates and inactivates the Src family members reduces phagocytosis [117] . It also involves Syk. Indeed, macrophages and neutrophils derived from the fetal livers of Syk-deficient mice fail to ingest IgG coated particles [118, 119] . Intracellular signaling also involves casein-kinase II [120] . Implication of calcium ions in FcγR is controversial; some studies evoke a plausible involvement of calcium ions fluxes [121] whereas some others deny it [122] . Calcium ions, however, play an important role in the phagosome-lysosome fusion [123] . FcγR-mediated phagocytosis also implicates PKC [124] , which regulates the cytoskeleton reorganization by phosphorylating other proteins such as MARCKS [125] . PI3K which acts on actin polymerization plays a role in the FcγR mediated phagocytosis of IgG-opsonized particles in neutrophils and macrophages [126] .
FcγR-mediated phagocytosis can induce an inflammatory reaction. The phagocytosis of IgG-opsonized beads by FcγR of microglial cells leads to the production of superoxide anion at phagosomal cup/phagosome through PKC [127] .
Microglial phagocytosis in neurodegenerative disease
Alzheimer's disease (AD) and multiple sclerosis are characterized by a cascade of inflammatory reactions eventually leading to neurodegeneration [128] . Microglia in both diseases may play a dual role, amplifying the effects of inflammation and mediating cellular degeneration as well as protecting the CNS [129] .
In multiple sclerosis (MS), lymphocytes and monocytes penetrate the white matter surrounding the blood vessels, destroying myelin and usually sparing axons. Macrophages and astrocytes play a major role in the inflammatory and immune responses in the CNS as well as in demyelination in MS. Xiao and Link [130] proposed that the balance between microglia and astrocytes and their interaction also play a significant role in multiple sclerosis activity. Microglia constitutively expresses MHC class II molecules, a phenomenon that is largely increased in response to infection and inflammation and is associated with neuronal damage. Sanders et al. [131] demonstrated the importance of microglia in the demyelinating process of multiple sclerosis.
In AD, a disturbed balance between the production and the degradation of betaamyloid peptide (Aβ) can trigger chronic inflammatory processes in microglial cells and astrocytes and thus initiate a vicious circle [132] . Inflammatory components related to AD include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors, peroxisomal proliferators-activated receptors, as well as cytokines and chemokines [133] . Although neuritic plaques have long been identified as significant elements in the neuropathogenesis of AD, the course of events leading to pathological alterations remains unknown. It is generally believed that Aβ is responsible for the synaptic and neuronal dysfunction and loss in AD [134] . Moreover, it is involved in the activation of microglia: exposure of microglia to Aβ leads to an increase in cell surface expression of MHC II [31] and it can cause peripherally circulating macrophages to cross the blood-brain barrier via chemokine recruitment [135] .
It is worth noting that non-steroidal anti-inflammatory drugs may reduce the risk for AD: ibuprofen can significantly delay some forms of AD pathology, including amyloid deposition, when administered early in the disease course of a transgenic mouse model of AD [136] . New studies have shown the implication of peroxisomal proliferators-activated receptors-γ in the control of Aβ-induced inflammation suggesting a new target for AD therapy and underlining the contribution of neuroinflammatory mechanisms to the pathogenesis of AD [137] .
Myelin phagocytosis by microglial cells
Microglial cells play an important role in the responses of CNS to injury or disease; one of these roles is the phagocytic removal of degenerated myelin. This function is especially efficient in CNS auto-demyelinating diseases such as multiple sclerosis even though the effect of myelin removal by microglia on the development of the pathology is unknown. Indeed, phagocytosis of myelin debris in situ seems protective whereas stripping myelin lamella from axons is rather detrimental. This Dr. Jekyll and Mr. Hyde behavior of microglia can be related to and contribute to the succession of relapses and remissions of the initial phase of multiple sclerosis.
CR3 has the potential of efficiently mediating myelin removal through a complementdependent or independent mode. However, the presence of complement improved myelin uptake [138] . Recent studies have shown that CR3-mediated myelin phagocytosis can be modulated by monoclonal antibodies (mAb) that bind to distinct epitopes of subunits αM and β-2 of CR3. αM-specific mAb inhibited, whereas β-2-specific mAb increased myelin phagocytosis. This mAb-induced modulation of myelin phagocytosis occurred on the complement-dependent and complement-independent pathways. These results suggest that a direct binding site for myelin exists on CR3 and that this site is probably on αM [138] . In microglial cells, complement receptors are also implicated in the phagocytosis of myelin opsonized with proteins from the complement cascade [139] .
Other receptors have been implicated and appear to be important in the attachment to and ingestion of myelin particle debris in vitro, including the FcγR [140] , SR-AI/II [141, 142] , LDL related-protein [143] and MR [144] . The elimination of myelin through FcγR requires anti-myelin antibodies and implies the same mechanisms than those describe above. Consistent with the hypothesis that SR-A participates in removal of damaged myelin, SR-A-/-mice develop significantly more "onion bulb" (histopathological structures observed in demyelinating polyradiculopathy and diabetic neuropathy) after compression injury of peripheral nerve than do wild type mice [145] .
In a myelin-phagocytosis assay that excluded involvement of FcγR, the analysis of the signal transduction in three macrophage populations (one expressing CR3 and SR-AI/II, another expressing only CR3 and the latter expressing only SR-AI/II) has shown that the two receptors share the following cascade PI3K → phospholipase C γ (PLCγ) → and classical protein kinase C (cPKC) [146, 147] .
Astrocytes modulate the phagocytosis of myelin in vitro: stimulation of microglia by astrocytes is due to an adhesion component, as well as to soluble factors secreted by the astrocytes. Indeed, microglial cells are equally stimulated by astrocyte-conditioned medium or when plated on an astrocyte monolayer [143] . Uptake of myelin by microglia is stimulated by pro-inflammatory IFNγ and inhibited by anti-inflammatory IL-4 [143] . In another study, TGF-β2 suppressed spontaneous myelin phagocytosis by microglia in a mouse ex vivo assay of CNS and peripheral nervous system Wallerian degeneration [148] . Investigation of the signalization pathways triggered by cytokine action during myelin phagocytosis is important for a further understanding of the events leading to myelin destruction in demyelinating diseases.
Ingestion of myelin results in increased NO release and decreased superoxide anion production, the effect being more pronounced when myelin is opsonized with complement [97] .
Elimination of β-amyloid peptide by microglial cells
β-amyloid peptide (Aβ) is produced in both normal and AD patients' brains. However, its deposition in the brains of AD patients suggests that there are clearance mechanisms and the accumulation of Aβ in AD brains is due to an imbalance between production and clearance. Three mechanisms contribute to the elimination of Aβ. Each of them could be impaired in AD: (a) extracellular proteolysis catalysed by neprilysin or insulin-degrading enzyme, two metalloproteases able to degrade Aβ [149, 150] ; (b) transfer across the BBB implicating the gp330/megalin receptor and its ligand apolipoprotein J which interacts with Aβ present in the cerebrospinal fluid [151, 152] and (c) receptor-mediated ingestion involving microglial receptors. It is worthy to note that receptors involved in this latter mechanism such as the low density lipoprotein receptor-related protein (LRP) could also be implicated in the tranfer across the BBB [153] . The reason why receptor-mediated ingestion of Aβ can be impaired is not understood. It has been shown that treatment with fibrillar Aβ 1-42 increased the phagocytosis of latex beads by microglia [23] . Therefore, the microglia that surrounds the dense-core amyloid plaques should have an enhanced ability to remove the deposit. It appears that this mechanism does not happen. The reason of this failure could be that the minor constituents of the senile plaques inhibit the phagocytosis or that the microglia is overwhelmed by the amount of deposited amyloid. Then, the phagocytic capacity is reduced whereas the cytotoxic capacity is enhanced: microglial cells release their lysosomal content and chronic inflammation is installed. Understanding the mechanism underlying the removal of Aβ by microglial receptors is therefore of great interest.
Elimination of Aβ in vivo
Microglial transformation from primed, to enlarged, to phagocytic phenotypes occurs with the evolution of amyloid plaques from diffuse amyloid deposits to the neuritic Aβ plaques form seen in the brains of AD patients [154] . In the first study demonstrating the intracellular presence of amyloid fibrils in microglial cells associated to classical plaques in brain cortex of patients with AD, the fibrils appeared first in altered endoplasmic reticulum and deep infoldings of cell membranes [155] . This means that microglial cells associated with amyloid plaques were engaged in the production of Aβ, but not in phagocytosis of Aβ. Later studies of topographic and functional relationships between microglial cells and senile plaque cores in AD brains conversely allowed one to conclude that the microglial cells participate in phagocytosis of Aβ and do not produce it [156] . Both statements of function are not mutually exclusive, and since microglial cells express the Amyloid Precursor Protein [APP], then they can produce it and eliminate it. Many studies confirm both aspects of these theories: brain macrophages containing granules immunopositive for C-terminal but not for N-terminal fragment of Aβ were believed to be able to engulf and digest Aβ fibrils [157] ; at the ultrastructural level, the cytoplasm of microglial cells located between amyloid core and neuritis are shown to contain amyloid fibrils or/and phagocytic bodies, suggesting therefore that these cells participate in the formation of amyloid fibrils and/or phagocytosis of amyloid fibrils [158] . However none of these studies could prove whether that Aβ was associated to a secretory, phagocytic or endocytotic pathway.
Studies using brains of animal models of AD did not provide much more information than those using human AD brains. Indeed, Aβ deposits are closely associated with microglial cells [159] and three-dimensional reconstruction revealed that microglia-engulfed amyloid fibrils were connected to extracellular amyloid deposits in the brain of APP23 mice [160] . Injection of amyloid cores isolated from AD patients brains or Aβ into the cortex and hippocampus of rats showed that phagocytic cells could internalize exogenous amyloid and attempted to clear it from the CNS [161, 162] .
Elimination of Aβ by microglial cells in vitro
It has been shown for a decade now that fibrillar synthetic Aβ can be catabolized by microglial cells and found in phagosome-like intracellular vesicles in vitro [163] . More interestingly, microglial cells rapidly ingest, break apart, and clear isolated senile plaques cores as well [164] . However, in vivo, the ability of microglial cells to phagocyte and degrade amyloid peptides seems to be suppressed by astrocytes and subcomponents of senile plaques, suchs as proteoglycans which slow the degradation of Aβ [164, 165] . It is also possible that microglial cells in AD brain have lost some functions like monocytes: monocytes from control subjects differentiate into macrophages and clear Aβ more efficiently than those from AD patients which barely differentiate into macrophages and do not eliminate Aβ [166] .
Intensive studies have tried to identify the receptors implicated in the recognition and the internalization of Aβ fibrils. SR-A and SR-B have been proposed as main candidates for this function, since uptake of fibrillar Aβ is reduced in presence of SR ligands; in addition, SR-A or SR-B-transfected-CHO cells displayed significantly enhanced uptake of Aβ [167] . However, fibrillar Aβ is internalized by SR receptors through an endocytotic and not a phagocytic mechanism since it was colocalized in the endosomes with α-2-macroglobulin [α2M] even though ligands of LRP, the α2M receptor, do not interfere with this internalization [167] . In vivo, SR-B plays a more important role in the removal of Aβ than SR-A since the disruption of SR-A does not affect the amyloid deposition in a transgenic model of Alzheimer's disease [168] . In a phagocytosis assay, we have shown that microglial cells recognize artificial deposits of fibrillar Aβ 1-42 and mediate their phagocytosis through LRP and not SR-A. Artificial deposits of fibrillar Aβ 1-40 are internalized as well by the microglial cells thanks to another receptor which still remains to be determined. These artificial deposits were made of particles coated with fibrillar Aβ 1-40 or Aβ 1-42 [28] .
It is therefore probable that microglial cells are able to bind fibrillar Aβ through a range of receptors that can cooperate for its elimination. Such a possibility has been recently suggested in a study which characterized an Aβ cell surface receptor complex consisting of the CD36, α6β1 integrin, and CD47 (integrin-associated protein) [169] . The binding of fibrillar Aβ to this cluster results in the activation of tyrosine kinase-based signaling cascades, leading to an acquisition of a proinflammatory phenotype [170, 171] .
Once ingested by microglial cells, fibrillar Aβ 1-42 is partly resistant to lysosomial degradation and can persist in microglial cell endosomes for at least 12 days [172, 173] . A large fraction of the ingested fibrillar Aβ is even released without any degradation [173] .
Endocytosis of Aβ by microglial cells is affected by different substances: estrogens increase the ingestive capacity of microglial cells whereas treatment with ICI 182,780, an estrogen receptor antagonist, showed a significantly reduced internalization of Aβ in cultured microglia [174] . Complement component C1q inhibits fibrillar Aβ uptake by microglial cells which may contribute to the accumulation of fibrillar, C1q-containing plaques that occurs in parallel with disease progression [175] . Recent studies have shown a close interaction between CD14 (LPS receptor) and fibrillar Aβ 1-42 in human CD14-transfected CHO cells, demonstrating a direct role of CD14 in Aβ 1-42 phagocytosis [176] .
Several studies have shown that microglial cells can eliminate Aβ in monomeric or nonfibrillar state. However, this kind of clearance does not implicate SR-A but pinocytosis pathway [173] . Non-fibrillar Aβ joins with the fibrillar peptides in the late endosomal compartment; this fact approves with the theory of microglial cell implication in the formation of amyloid fibrils. These results also suggest that formyl peptide-receptorlike-1 (FPRL1) is also involved in the internalization of Aβ 1-42, which leads to the formation of fibrils only in macrophages, besides mediating the proinflammatory activity of this peptide. Upon incubation of non fibrillar Aβ 1-42 with macrophages or HEK 293 cells genetically engineered to express FPRL1, Aβ 1-42 associated with FPRL1 and the Aβ 1-42/FPRL1 complexes were rapidly internalized into the cytoplasmic compartment. However, persistent exposure of the cells to Aβ 1-42 over 24 h resulted in retention of Aβ 1-42/FPRL1 complexes in the cytoplasmic compartment and the formation of Congo red positive fibrils in macrophages but not in HEK 293 cell transfected with FPRL1 [177] .
Several proteins can lead to the internalization of amyloid peptide by mediating the interaction with their receptor, which does not necessarily recognize Aβ alone. Lactoferrin [178] , α2M [178, 179] and ApoE [180] can bind Aβ and their receptor. LRP recognizes and internalizes these complexes (protein-Aβ) in microglial cells, neurons or cells genetically modified for expressing LRP.
Antibody-mediated elimination of Aβ
An alternative mechanism for microglial cells to eliminate the amyloid deposits is to coat them with opsonins and phagocytose the opsonized Aβ thanks to the opsonin-dependent receptors. It has been possible to reduce the Aβ levels, inhibit amyloid deposition and clear preexisting plaques in mouse models of AD after an Aβ 1-42 immunization [181] . Later on, it has been shown that even a passive immunization with anti-Aβ antibody reduces the pathology in PDAPP mice (mice transgenic for human APP gene placed under the control of human platelet derived growth factor gene promoter) thanks to a mechanism acting in the brain, since the antibody was found in the CNS [182] . In an ex vivo assay, the FcγR was shown to be implicated in the elimination of Aβ by microglia since F(ab')2 of the same antibody was unable to eliminate the Aβ deposit suggesting that the very same mechanism was operating in the brain of the immunized mice. The AD-like pathology reduction in the mice depends on the IgG isotypes injected. Indeed, an anti-Aβ IgG2a monoclonal antibody mAb (higher affinity for FcγRI) reduces more dramatically Aβ deposition compared with anti-Aβ IgG2b or IgG1 isotypes. Therefore, a potential role for FcγR-mediated mechanisms is plausible [183] . The site of entry of the antibody is important as well: an intra venous injection instead of an intra peritoneal (i.p.) injection leads to a reduction of the pathology in the same AD model, thanks to a peripheral action of the antibody that bound to the plasmatic Aβ and induced an efflux of the Aβ from the brain into the plasma [184] . An intracranial injection may have the same effect than an i.p. injection since a close association of amyloid loss with microglial activation (up to 3 days after antibody injection) was observed [185] . One possibility is that the activated microglial cells phagocytosed the opsonized Aβ through FcγR.
However, other evidence shows that reduction of amyloid after Aβ immunization involves non Fc-mediated mechanisms as well [186, 187] . It is still possible that these mechanisms would be dependent upon a phagocytic removal by microglia since it is well known that once the antibody-antigen complexes trigger the complement cascade, the C3b and iC3b bind the immune complexes and mediate their removal by macrophage complement receptor CR3.
